Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RH127
- Development stage
- Preclinical
- Lead developer
- Shenzhen Rhegen Biotechnology
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RH127 is a preclinical **mRNA combination vaccine** being developed by Shenzhen Rhegen Biotechnology for prevention of infections caused by respiratory syncytial virus and human metapneumovirus. The vaccine is designed to encode antigens from both respiratory viruses and elicit protective antiviral immune responses against RSV and hMPV.
- Other names
- Pan-respiratory Combination Vaccine泛呼吸道联苗
Beyond the preview
Go deeper on RH127.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RH127.